Over 20% of ER-positive/ERBB2(HER2)-normal and ERBB2-amplified exhibited cyclin D1 gene amplification in breast cancer patient data from The Cancer Genome Atlas (TCGA). This evidence concerns the gene ESR1 and breast carcinoma.